Frazier Life Sciences Discloses 9.9% Passive Stake in Oric Pharma

TL;DR

**Frazier Life Sciences just revealed a 9.9% passive stake in Oric Pharma, signaling institutional confidence.**

AI Summary

Frazier Life Sciences Public Fund, L.P. and its affiliated entities, including Frazier Life Sciences X, L.P. and Frazier Life Sciences XI, L.P., reported a significant passive ownership stake in Oric Pharmaceuticals, Inc. As of January 23, 2024, this group collectively holds 4,498,000 shares of Oric's Common Stock, representing 9.9% of the company. This matters to investors because a major institutional investor taking a large, passive stake can signal confidence in the company's long-term prospects, potentially attracting other investors and influencing stock stability.

Why It Matters

This filing reveals a major institutional investor's significant stake, which can be seen as a vote of confidence in Oric Pharmaceuticals and may influence market perception.

Risk Assessment

Risk Level: low — This is a passive filing, indicating no immediate intent to influence company control, which generally poses low risk to existing shareholders.

Analyst Insight

A smart investor would view this as a positive signal, suggesting institutional confidence in Oric Pharmaceuticals, and might consider further research into the company's fundamentals and pipeline.

Key Numbers

• 4,498,000 — Shares Beneficially Owned (Total shares of Oric Pharmaceuticals Common Stock held by Frazier Life Sciences and its affiliates.)
• 9.9% — Percentage of Class (The percentage of Oric Pharmaceuticals' Common Stock beneficially owned by the reporting group.)
• January 23, 2024 — Date of Event (The date on which the event requiring this SC 13G filing occurred.)

Key Players & Entities

• Frazier Life Sciences Public Fund, L.P. (company) — filing entity and major shareholder
• Oric Pharmaceuticals, Inc. (company) — subject company of the filing
• Frazier Life Sciences X, L.P. (company) — group member and affiliated entity
• Frazier Life Sciences XI, L.P. (company) — group member and affiliated entity
• Albert Cha (person) — group member
• Daniel Estes (person) — group member
• James Brush (person) — group member
• James N. Topper (person) — group member
• Patrick J. Heron (person) — group member

Forward-Looking Statements

• Oric Pharmaceuticals' stock price may experience increased stability due to institutional backing. (Oric Pharmaceuticals, Inc.) — medium confidence, target: next 3-6 months
• Other institutional investors might initiate or increase their positions in Oric Pharmaceuticals, following Frazier's lead. (Oric Pharmaceuticals, Inc.) — low confidence, target: next 6-12 months

FAQ

Filing Documents

• d709301dsc13g.htm (SC 13G) — 293KB
• d709301dex99a.htm (EX-99.A) — 28KB
• 0001193125-24-015197.txt ( ) — 323KB

From the Filing

SC 13G 1 d709301dsc13g.htm SC 13G SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ORIC Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68622P109 (CUSIP Number) January 23, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ). CUSIP No. 68622P109 1. Names of Reporting Persons Frazier Life Sciences Public Fund, L.P. 2. Check the Appropriate Box if a Member of a Group (see instructions) (a)(b) 3. SEC USE ONLY 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 0 shares 6. Shared Voting Power 1,778,989 shares (1) 7. Sole Dispositive Power 0 shares 8. Shared Dispositive Power 1,778,989 shares (1) 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,778,989 shares (1) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) 11. Percent of Class Represented by Amount in Row 9 2.7% (2) 12. Type of Reporting Person (see instructions) PN (1) Consists of 1,778,989 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. (2) Based on (i) 54,551,290 shares of Common Stock outstanding on October 31, 2023, as set forth in the Issuers Form 10-Q filed with the SEC on November 6, 2023, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its private placement offering as described in the Issuers Current Form 8-K filed with the SEC on January 20, 2024. CUSIP No. 68622P109 1. Names of Reporting Persons FHMLSP, L.P. 2. Check the Appropriate Box if a Member of a Group (see instructions) (a) (b) 3. SEC USE ONLY 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 0 shares 6. Shared Voting Power 1,778,989 shares (1) 7. Sole Dispositive Power 0 shares 8. Shared Dispositive Power 1,778,989 shares (1) 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,778,989 shares (1) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) 11. Percent of Class Represented by Amount in Row 9 2.7% (2) 12. Type of Reporting Person (see instructions) PN (1) Consists of 1,778,989 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. (2) Based on (i) 54,551,290 shares of Common Stock outstanding on October 31, 2023, as set forth in the Issuers Form 10-Q filed with the SEC on November 6, 2023, and (ii) 12,500,000 shares of Common Stock that were sold by the Issuer in connection with its private placement offering as described in the Issuers Current Form 8-K filed with the SEC on January 20, 2024. CUSIP No. 68622P109 1. Names of Reporting Persons FHMLSP, L.L.C. 2. Check the Appropriate Box if a Member of a Group (see instructions) (a)(b) 3. SEC USE ONLY 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 0 shares 6. Shared Voting Power 1,778,989 shares (1) 7. Sole Dispositive Power 0 shares 8. Shared Dispositive Power 1,778,989 shares (1) 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,778,989 shares (1) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares

View Full Filing

View this SC 13G filing on SEC EDGAR